Survival-Associated Metabolic Genes and Risk Scoring System in HER2-Positive Breast Cancer

Abstract

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple-negative breast cancer have their own genetic, epigenetic, and protein expression profiles. In the present study, based on bioinformatics techniques, we explored the prognostic targets of HER2-positive breast cancer from metabonomics perspective and developed a new risk score system to evaluate the prognosis of patients. By identifying the differences between HER2 positive and normal control tissues, and between triple negative breast cancer and normal control tissues, we found a large number of differentially expressed metabolic genes in patients with HER2-positive breast cancer and triple-negative breast cancer. Importantly, in HER2-positive breast cancer, decreased expression of metabolism-related genes ATIC, HPRT1, ASNS, SULT1A2, and HAL was associated with increased survival. Interestingly, these five metabolism-related genes can be used to construct a risk score system to predict overall survival (OS) in HER2-positive patients. The time-dependent receiver operating characteristic (ROC) curve analysis showed that the predictive sensitivity of the risk scoring system was higher than that of other clinical factors, including age, stage, and tumor node metastasis (TNM) stage. This work shows that specific transcriptional changes in metabolic genes can be used as biomarkers to predict the prognosis of patients, which is helpful in implementing personalized treatment and evaluating patient prognosis.

Exploitation of a shared genetic signature between obesity and endometrioid endometrial cancer

“…Integrating previous reports and bioinformatics analysis, we hypothesized that ANG expression is associated with obesity and involved in EC progression by affecting tumor angiogenesis. SULT1A2 encodes phenol sulfotransferases involved in hormone metabolism and has been reported to be associated with the prognosis of patients with HER2-positive breast cancer ( 16 ). Also, as estrogen-dependent tumors, the development of EEC may be influenced by SULT1A2 expression.…”

Bibliometric analysis and visualization of endocrine therapy for breast cancer research in the last two decade

“…It encompasses the historical development of this treatment modality, including milestones such as the discovery of tamoxifen and aromatase inhibitors ( 17 , 18 ). The emergence of novel agents and combination therapies, along with the identification of predictive biomarkers ( 19 ), is reshaping the landscape of breast cancer treatment ( 20 ), such that new avenues are provided for personalized treatment. Its remarkable success in improving survival rates and enhancing the quality of life for patients underscores its significance ( 21 – 23 ).…”

Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report

“…Breast cancer is a heterogeneous disease with multiple subtypes, each of which (Luminal type, HER2 + type, triple-negative breast cancer) all have unique clinical, pathological, and molecular features (2,3). HER2 is an epidermal growth factor receptor that is highly expressed in 20% of breast cancers (4).…”

“…Breast cancer is a heterogeneous disease with multiple subtypes, each of which (Luminal type, HER2 + type, triple-negative breast cancer) all have unique clinical, pathological, and molecular features ( 2 , 3 ). HER2 is an epidermal growth factor receptor that is highly expressed in 20% of breast cancers ( 4 ). Anti-HER2 therapy has become the standard treatment for breast cancer patients with high HER2 expression, and a variety of anti-HER2 drugs, including trastuzumab, have achieved good clinical results ( 5 ).…”